- Published at
- by manilatimes.net
mixed
mixed
News for HLB Co., Ltd. (028300.KQ)
- Published at
- by gurufocus.com
positivepositiveElevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors
Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008) Lirafugratinib is a potential bes- Published at
- by globenewswire.com
positivepositiveElevar Therapeutics Granted Orphan Medicinal Product Designation by the European Medicines Agency for First-Line Systemic Therapy for Unresectable Hepatocellular Carcinoma
FORT LEE, N.J., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd., today announced the European...- Published at
- by globenewswire.com
neutralneutralElevar Therapeutics Reports Landmark Median Overall Survival of 23.8 Months in First-Line Treatment for Unresectable Hepatocellular Carcinoma
Phase 3 CARES-310 study found combination of camrelizumab and rivoceranib continued to show sustained long-term survival compared with sorafenib as a...- Published at
- by insidermonkey.com
mixedmixed- Published at
- by globenewswire.com
neutralneutralGlass Reinforced Plastic Market Surges Towards USD 69 billion by 2031 with 4.8% CAGR | Exclusive Report by Transparency Market Research, Inc.
Growth in the transportation, electrical and electronics, and building and construction industries is a significant driver driving the glass reinforced...- Published at
- by globenewswire.com
negativenegativeElevar Therapeutics to Host August 10 Virtual KOL Event on Phase 3 Study of Rivoceranib in Combination with Camrelizumab in Unresectable Hepatocellular Carcinoma (uHCC)
FORT LEE, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated...- Published at
- by globenewswire.com
negativenegativeElevar Therapeutics Announces FDA Acceptance for Filing of New Drug Application for Rivoceranib in Combination with Camrelizumab as a First-line Treatment for Unresectable Hepatocellular Carcinoma
With a standard review, FDA set a PDUFA target action date of May 16, 2024...- Published at
- by globenewswire.com
negativenegativeGlass Reinforced Epoxy (GRE) Pipes Market to Grow at CAGR of 4.8% During Forecast Period, Notes TMR Study
Anti-mite and antifouling qualities of GRE pipes are likely to drive its demand in the market. It renders the resin's surface clean and smooth,...- Published at
- by marketscreener.com
neutralneutralImmunomic's Academic Collaborator Dr. John Sampson Recognized as “World Expert” in Glioblastoma as Part of Glioblastoma Awareness Day
Immunomic Therapeutics, Inc., a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today that its’ academic...